Concepedia

Hiromi Sugimoto

HS

Statistics

Publications

13

Citations

561

H-Index

11

Active since

1985

Affiliations

Pfizer (Japan)(Current)

Shionogi (Japan)

Kyoto University

Hiromi Sugimoto is an author at Pfizer (Japan) specializing in pharmacology, medicine, and cell signaling.

Publications per year

1985–2020

13

Publications

13

An Orally Bioavailable Small Molecule Antagonist of CRTH2, Ramatroban (BAY u3405), Inhibits Prostaglandin D2-Induced Eosinophil Migration in Vitro

Hiromi Sugimoto, Michitaka Shichijo, Takashi Iino et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 159 citations

Medicine, Immunology, Pharmacology +17

Pharmacological Evaluation of a Novel Cannabinoid 2 (CB2) Ligand, PF-03550096, In Vitro and In Vivo by Using a Rat Model of Visceral Hypersensitivity

Akira Kikuchi, Katsuyo Ohashi, Yutaka Sugie et al. · Journal of Pharmacological Sciences · 2008 · 66 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +11

Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells Activation in Vivo Increases Blood Leukocyte Counts and Its Blockade Abrogates 13,14-Dihydro-15-keto-prostaglandin D2-Induced Eosinophilia in Rats

Michitaka Shichijo, Hiromi Sugimoto, Kōichi Nagao et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 64 citations

Life Sciences, Immunology, Pharmacology +17

Interactions of Endothelin Receptor Subtypes A and B with G<sub>i</sub>, G<sub>o</sub>, and G<sub>q</sub>in Reconstituted Phospholipid Vesicles

Tomoko Doi, Hiromi Sugimoto, Ikuyo Arimoto et al. · Biochemistry · 1999 · 60 citations

Life Sciences, Biochemistry, Pharmacology +17

Effects of pirfenidone in acute and sub-chronic liver fibrosis, and an initiation-promotion cancer model in the mouse

Oleksii Seniutkin, Shinji Furuya, Yu‐Syuan Luo et al. · Toxicology and Applied Pharmacology · 2017 · 42 citations

Medicine, Oncology, Pharmacology +14

1–5 of 13